Safe and Effective Cynomolgus Monkey GLP-Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders.

Sebastian Peters; Eva Wirkert; Sabrina Kuespert; Rosmarie Heydn; Siw Johannesen; Anita Friedrich; Susanne Mailänder; Sven Korte; Lars Mecklenburg; Ludwig Aigner; Tim-Henrik Bruun; Ulrich Bogdahn

doi:10.3390/pharmaceutics14010200

Safe and Effective Cynomolgus Monkey GLP-Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders.

Sebastian Peters, Eva Wirkert, Sabrina Kuespert, Rosmarie Heydn, Siw Johannesen, Anita Friedrich, Susanne Mailänder, Sven Korte, Lars Mecklenburg, Ludwig Aigner (Co-author), Tim-Henrik Bruun, Ulrich Bogdahn

Research output: Contribution to journal › Original Article › peer-review

3 Citations (Web of Science)

Original language	English
Journal	PHARMACEUTICS
Volume	14
Issue number	1
DOIs	https://doi.org/10.3390/pharmaceutics14010200
Publication status	Published - 2022

Keywords

AMYOTROPHIC-LATERAL-SCLEROSIS
RILUZOLE
BETA
INHIBITION
NUSINERSEN
INJURY
AGENT

Access to Document

10.3390/pharmaceutics14010200

Cite this

Peters, S., Wirkert, E., Kuespert, S., Heydn, R., Johannesen, S., Friedrich, A., Mailänder, S., Korte, S., Mecklenburg, L., Aigner, L., Bruun, T.-H., & Bogdahn, U. (2022). Safe and Effective Cynomolgus Monkey GLP-Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders. PHARMACEUTICS, 14(1). https://doi.org/10.3390/pharmaceutics14010200

@article{511214872c5242e1895bc81fcd0057e4,

title = "Safe and Effective Cynomolgus Monkey GLP-Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders.",

keywords = "AMYOTROPHIC-LATERAL-SCLEROSIS, RILUZOLE, BETA, INHIBITION, NUSINERSEN, INJURY, AGENT",

author = "Sebastian Peters and Eva Wirkert and Sabrina Kuespert and Rosmarie Heydn and Siw Johannesen and Anita Friedrich and Susanne Mail{\"a}nder and Sven Korte and Lars Mecklenburg and Ludwig Aigner and Tim-Henrik Bruun and Ulrich Bogdahn",

note = "Lehr-KH Murnau: Johannesen: BG Trauma Center; Aigner, Ludwig: Institute of Molecular Regenerative Medicine, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University Salzburg, 5020 Salzburg, Austria",

year = "2022",

doi = "10.3390/pharmaceutics14010200",

language = "English",

volume = "14",

journal = "PHARMACEUTICS",

issn = "1999-4923",

publisher = "MDPI",

number = "1",

}

Peters, S, Wirkert, E, Kuespert, S, Heydn, R, Johannesen, S, Friedrich, A, Mailänder, S, Korte, S, Mecklenburg, L, Aigner, L, Bruun, T-H & Bogdahn, U 2022, 'Safe and Effective Cynomolgus Monkey GLP-Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders.', PHARMACEUTICS, vol. 14, no. 1. https://doi.org/10.3390/pharmaceutics14010200

Safe and Effective Cynomolgus Monkey GLP-Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders. / Peters, Sebastian; Wirkert, Eva; Kuespert, Sabrina et al.
In: PHARMACEUTICS, Vol. 14, No. 1, 2022.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Safe and Effective Cynomolgus Monkey GLP-Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders.

AU - Peters, Sebastian

AU - Wirkert, Eva

AU - Kuespert, Sabrina

AU - Heydn, Rosmarie

AU - Johannesen, Siw

AU - Friedrich, Anita

AU - Mailänder, Susanne

AU - Korte, Sven

AU - Mecklenburg, Lars

AU - Aigner, Ludwig

AU - Bruun, Tim-Henrik

AU - Bogdahn, Ulrich

N1 - Lehr-KH Murnau: Johannesen: BG Trauma Center; Aigner, Ludwig: Institute of Molecular Regenerative Medicine, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University Salzburg, 5020 Salzburg, Austria

PY - 2022

Y1 - 2022

KW - AMYOTROPHIC-LATERAL-SCLEROSIS

KW - RILUZOLE

KW - BETA

KW - INHIBITION

KW - NUSINERSEN

KW - INJURY

KW - AGENT

U2 - 10.3390/pharmaceutics14010200

DO - 10.3390/pharmaceutics14010200

M3 - Original Article

C2 - 35057094

SN - 1999-4923

VL - 14

JO - PHARMACEUTICS

JF - PHARMACEUTICS

IS - 1

ER -